|
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study. |
| |
|
Consulting or Advisory Role - Janssen; Photocure |
Speakers' Bureau - Urogen pharma |
| |
|
Honoraria - Combat Medical; Janssen; Pfizer |
Consulting or Advisory Role - Combat Medical; Janssen; Pfizer; Roche |
Travel, Accommodations, Expenses - Combat Medical; Janssen; Pfizer |
| |
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Janssen; MSD; Pfizer |
Travel, Accommodations, Expenses - IPSEN,; Janssen |
| |
|
No Relationships to Disclose |
| |
|
Stock and Other Ownership Interests - C2i genomics; CAPs medical; Nanorobotics; Phinomics; Uroviu; Vessi Medical; Virtuoso Therapeutics |
Consulting or Advisory Role - Abbvie; Ambu; AstraZeneca; Aura Biosciences; BMS; C2i genomics; caps medical; Cleveland Diagnostics; Convergent Genomics; Fergene; Merck; Nanogen Biopharmaceutical; Nanorobotics; Nucleix; pacific edge; phinomics; Photocure; Seagen; Stimit; Urogen pharma; uroviu; verity pharmaceuticals; Vessi Medical; virtuoso surgical; Xcures |
Research Funding - Abbott Molecular (Inst); Augmenix; BioCancell (Inst); Cepheid; Cepheid (Inst); GenomeDx (Inst); MDxHealth (Inst); pacific edge; pacific edge (Inst); Photocure (Inst); storz (Inst) |
| |
Christopher Michael Pieczonka |
Employment - Associated Medical Professionals of New York |
Leadership - Associated Medical Professionals of New York |
Stock and Other Ownership Interests - US Urology Partners |
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Janssen; Merck; Myovant Sciences; Pfizer/Astellas; Sun Pharma |
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Janssen Oncology; Merck; Pfizer/Astellas; Sun Pharma; Sun Pharma; Tolmar |
Speakers' Bureau - Astellas Pharma; Bayer; Dendreon; Foundation Medicine; Janssen Oncology; Myovant Sciences; Pfizer; Sun Pharma |
Research Funding - Advantagene; Astellas Pharma; AstraZeneca; Bayer; Dendreon; Janssen Oncology; Merck; Pfizer |
| |
|
Research Funding - Janssen |
Travel, Accommodations, Expenses - European Association of Urology |
| |
|
|
Stock and Other Ownership Interests - Bayer (I) |
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Foundation Medicine; Janssen; Merck; Roche |
Consulting or Advisory Role - AstraZeneca; Basilea Pharmaceutical; Bayer; Bristol-Myers Squibb; Catalym; Clovis Oncology; GlaxoSmithKline; Incyte; Janssen; Merck Sharp & Dohme; Rainier Therapeutics; Roche; Seattle Genetics/Astellas |
Research Funding - AstraZeneca (Inst); Gilead Sciences; Ipsen; Merck Sharp & Dohme (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Merck Sharp & Dohme; Pfizer; Rainier Therapeutics; Roche |
Other Relationship - Bayer (I) |
| |
|
Honoraria - Abbvie; AstraZeneca Canada; Bayer; BioSyent; Knight Pharmaceuticals; Tersera |
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Ferring; Janssen Oncology; Merck; Theralase; Verity Pharmaceuticals |
| |
|
Honoraria - Astellas Pharma; AstraZeneca; Ferring; Janssen |
| |
|
Consulting or Advisory Role - AstraZeneca; Janssen |
| |
|
No Relationships to Disclose |
| |
|
Employment - Janssen; Janssen |
Honoraria - Advanced Accelerator Applications; Amgen; Astellas Pharma; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Janssen-Cilag; Merck; MSD; Novartis; Pfizer; Roche; Sanofi/Aventis |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; ipsen; Janssen-Cilag; Merck; MSD; Novartis; Roche; Sanofi |
Research Funding - IPSEN (Inst); Janssen-Cilag |
Travel, Accommodations, Expenses - Amgen; Bayer; BMS GmbH & Co. KG; Janssen-Cilag |
| |
|
No Relationships to Disclose |
| |
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
| |
|
|
Stock and Other Ownership Interests - Johnson & Johnson |
| |
Michiel Simon Van Der Heijden |
Stock and Other Ownership Interests - Gilead Sciences |
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst) |
Research Funding - 4SC (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Roche (Inst); Seagen (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; MSD Oncology; Novartis; Roche |